Single-dose Anti-CD20 Antibody With Bortezomib for Relapsed Refractory Autoimmune Hemolytic Anemia

Clinical trial NCT04083014 · COMPLETED

Trial details

NCT number: NCT04083014
Sponsor: Peking Union Medical College Hospital
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Autoimmune Hemolytic Anemia Autoimmune Hemolytic Anemia and Autoimmune Thrombocytopenia

Start date: 2019-08-20
Primary completion: 2024-03-01
Enrollment: 33

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.